ZEPHYRx, a cloud-based respiratory monitoring solutions provider, has partnered with NIOX, a world leader in FeNO testing, to enhance their clinical research offering via the integration of FeNO by NIOX into the ZEPHYRx Respiratory Cloud Platform. This collaboration will streamline respiratory endpoints used in clinical research and provide a single source of truth for health information technology needs.
ZEPHYRx is recognized for its advanced technology in respiratory monitoring solutions for clinical research. The company’s collaboration with NIOX aims to provide a seamless solution for FeNO by NIOX measurements by integrating them into the ZEPHYRx platform. NIOX, known for its FeNO testing solutions, is the primary partner to further expand clinical research offerings through their collaboration with ZEPHYRx.
According to Michael DiCesare, President and Cofounder of ZEPHYRx, this expansion of the platform has already had a significant impact on clinical trials supported by the company. He stated that ZEPHYRx’s objective is to serve as the single source of truth for various endpoints used in respiratory research, and the company has plans for additional integrations throughout 2024.
Tom Scaccia, NIOX Senior Vice President of the Americas and Research Business, expressed enthusiasm about the partnership, stating, “We are excited to be a partner with ZEPHYRx as they expand their platform capabilities.”
Measurements from the NIOX device are directly captured in the ZEPHYRx Respiratory Cloud Platform and are accessible in real-time through the Provider Dashboard. An updated feature recently released by ZEPHYRx allows researchers to view all endpoints in a single screen, with historical data trending and participant adherence monitoring. This feature also enables sponsors to monitor study site performance, allowing for prompt intervention to improve study outcomes.
ZEPHYRx is a leading provider of cloud-based respiratory monitoring solutions for health systems and clinical research. The ZEPHYRx Respiratory Cloud Platform offers solutions for both point-of-care and remote lung function testing with all data captured in a single source of truth. The company commits to providing the most comprehensive platform for respiratory endpoints to deliver a seamless experience to their customers and participants.
NIOX focuses on improving asthma diagnosis and management by providing greater patient access to FeNO testing. They have a market-leading device, NIOX VERO®, which is recognized as a vital tool for the diagnosis and management of asthma. Additionally, NIOX VERO® is the device of choice by leading clinical research organizations for respiratory studies.
The partnership between ZEPHYRx and NIOX aims to improve respiratory monitoring and clinical research by combining expertise and capabilities. With a shared commitment to enhancing health information technology and respiratory solutions, the collaboration between ZEPHYRx and NIOX holds great promise for advancing the field of respiratory research. For more information, please visit [ZEPHYRx’s website](https://www.zephyrx.com/) and [NIOX’s website](http://www.niox.com/).
Source link